Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q8NER5
UPID:
ACV1C_HUMAN
Alternative names:
Activin receptor type IC; Activin receptor-like kinase 7
Alternative UPACC:
Q8NER5; Q4ZFZ8; Q86UL1; Q86UL2; Q8TBG2
Background:
Activin receptor type-1C, also known as Activin receptor-like kinase 7, is a serine/threonine protein kinase. It forms a crucial part of the receptor complex involved in ligand binding, consisting of 2 type II and 2 type I transmembrane serine/threonine kinases. Upon activation, it plays a pivotal role in cell differentiation, growth arrest, and apoptosis by activating SMAD transcriptional regulators, SMAD2 and SMAD3. It serves as a receptor for activin AB, activin B, and NODAL.
Therapeutic significance:
Understanding the role of Activin receptor type-1C could open doors to potential therapeutic strategies.